US OptionsDetailed Quotes

KYMR241220C25000

Watchlist

22.10
0.000.00%

15min DelayClose Nov 29 12:59 ET

0.00High0.00Low

Kymera Therapeutics Stock Discussion

Spinee

Jul 15 02:41

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio?
$XPeng (XPEV.US)$ stock rose 15.56%. Shares of Chinese stocks gained following an increase in China's June exports.
$QuantumScape (QS.US)$ stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen $VOLKSWAGEN A G (VWAGY.US)$ 's battery company PowerC...

Meltyy

May 16 01:14

🔔 Baker Bros. Q1 ‘24* Holdings Released... 🐳

» Holdings: 87
» Holdings in Top 20: 86.71%
» Qtr over Qtr Change**: -9.29%
Top Holdings:
$Incyte (INCY.US)$
$BeiGene (BGNE.US)$
$ACADIA Pharmaceuticals (ACAD.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Revolution Medicines (RVMD.US)$
$Kymera Therapeutics (KYMR.US)$
$AbCellera Biologics (ABCL.US)$
$Bicycle Therapeutics (BCYC.US)$
$Edgewise Therapeutics (EWTX.US)$
$Immunocore (IMCR.US)$
$Kodiak Sciences (KOD.US)$
$Roivant Sciences (ROIV.US)$
...

Moomoo AI

Feb 25 07:56

Despite lower revenue forecasts, analysts see no long-term impact on the business's intrinsic value. Opinions vary, with the most optimistic analyst valuing it at US$112 and the most pessimistic at US$26.00 per share. No changes were made to next year's loss forecasts, but revenue estimates were downgraded. The company's long-term earnings trajectory is deemed more crucial than next year's performance.

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Analysts Are Pretty Bullish On The Stock After Recent Results

Moomoo AI

Dec 27, 2023 04:53

Kymera Therapeutics' high P/S ratio could imply investors' bullish stance outweighs analysts. However, without major growth improvement, the high P/S value may not sustain this positive sentiment, potentially making the stock overvalued.

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 35% Price Boost Is Out Of Tune With Revenues

Trytosaveabit

Dec 7, 2023 06:09

Update

$Kymera Therapeutics (KYMR.US)$ Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment From Sanofi

Trytosaveabit

Nov 6, 2023 17:55

Insider buy!

$Kymera Therapeutics (KYMR.US)$ Director BVF PARTNERS L P/IL purchased 414.11K shares of Common Stocks on Nov 2, 3, 2023 at an average price of $12.8019 for a total value of $5.3 million.
This transaction involves other related parties: BIOTECHNOLOGY VALUE FUND L P, BVF I GP LLC, BIOTECHNOLOGY VALUE FUND II LP, BVF II GP LLC, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., BVF GP HOLDINGS LLC, BVF INC/IL and LAMPERT MARK N.

Trytosaveabit

Nov 2, 2023 06:16

Gonna get worse?

$Kymera Therapeutics (KYMR.US)$ Kymera Therapeutics: KT-413 (IRAKIMiD) Development to Be Discontinued for Strategic Reasons >KYMR
Dow Jones· 6 mins ago

Moomoo AI

Oct 29, 2023 09:52

Though Kymera Therapeutics is increasing its cash burn and seeing reduced operating revenue, it's still well positioned. However, potential share dilution from issuing new shares to cover a year's operations could deter future investors.

Here's Why We're Watching Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Trytosaveabit

Oct 27, 2023 08:15

Really!

$Kymera Therapeutics (KYMR.US)$ 40Million in milestone payment and not a single trade in PM? hehehe! well ima put a lowball order and see if it fills? But you better believe i got that SL tight! hehehe

Trytosaveabit

Oct 27, 2023 06:05

News

$Kymera Therapeutics (KYMR.US)$ Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
4 MINUTES AGO, 7:00 AM EDT
VIA GLOBENEWSWIRE

No comment yet